TP53 and breast carcinoma: In order to assess whether the p53 status of the cells would influence the response to ARV-825, we investigated the effect of ARV-825 on sensitivity to TAM in the p53−/− MCF-7 ER+ breast cancer cell line where p53 had been silenced using CRISPR/Cas9.